Biogen has been soaring on news of its recent drug approval, but the question remains when it can keep it up. Here are the bullish and bearish arguments. More
-
-
Sponsored By:
-
Sponsored By:
CELG
Recent Articles
10 Best S&P 500 Stocks of Q1
Here’s a look at the 10 best performers in the S&P 500, as well as some thoughts about why they have rallied and what’s in store for them for the rest of the year. More
Pounce on This Biotech Favorite If it Falls Back Into Buying Range
Celgene Corp. (NASDAQ:CELG) broke from a rectangle consolidation, forming a steep bull channel. More
Get This Blazing Hot Biotech for a Reasonable Price
A consolidation in Celgene Corp. is giving traders the perfect opportunity to buy at a bargain. More
3 Healthcare Stocks Ready for a Breather
It's the hottest sector in the S&P 500 so far this year, and that means some big-name pullbacks are likely. Here are three likely candidates. More
What Stocks Will Thrive Under a Second Obama Term?
Healthcare is one of the more apparent beneficiaries of a second Obama term. Two companies -- a generic drug-maker and medical device company -- stand out. More
4 Reasons Celgene Is the Real Deal
Celgene has reached all-time highs in the wake of the firm’s boffo reviews at this week’s JPMorgan Healthcare Conference ... and it's still worth buying. More
